This study will be conducted to evaluate the safety and efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura. Sufficient number of patients will be enrolled in the study to get 25 evaluable subjects. Patient’s who meet all inclusion criteria and none of the exclusion criteria based on medical history will be recruited in the study. Patient’s visit 1 will be screening visit followed by treatment period and last will be follow up period for 1 week after last dose.

The eligible patient’s will be injected subcutaneously with initial dose for Romiplostim 1 mcg/kg based on actual body weight and then the weekly dose of Romiplostim will be adjusted by increment of 1 mcg/kg until the patient achieves a platelet count more than or equal to 50 count once a week for 12 cycles. The primary endpoint will be number of AEs (adverse events) and number of adverse drug reactions (ADRs) during the study period. The secondary endpoint will be number of serious adverse events (SAEs) and serious adverse drug reactions (SADRs) during the study period and proportion of patients achieving platelet response (achievement of a weekly platelet count more than or equal to 50 x 10 raise to 9 /L).